Oncologic Drugs Advisory Committee (ODAC)

New Capabilities

Reviewed camizestrant and Truqap applications on April 30, 2026

For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.

Updated May 31